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ABSTRACT
Introduction: To assess the use of nutritional support in children and adolescents 
submitted to autologous hematopoietic stem cell transplantation (HSCT), and analyze 
changes in nutritional status at hospital discharge after HSCT.
Methods: A retrospective observational study was conducted on pediatric oncology 
patients hospitalized for autologous HSCT between 2010 and 2017. Nutritional therapy 
was evaluated based on the duration of enteral tube feeding (ETF) and parenteral 
nutrition (PN), either alone or in combination. The length of hospital stay was measured 
in days. Nutritional status was assessed at admission and discharge, and classified 
according to World Health Organization criteria.
Results: The sample consisted of 68 patients, 54.4% of whom were boys. Most 
participants (89.7%) had solid tumors. Nutritional therapy was required in over half 
(52.9%) of cases, with PN being the most common indication. There was a reduction in 
the percentage of overweight patients and an increase in the percentage of underweight 
patients at discharge relative to admission. 
Conclusions: The use of nutritional therapy is highly prevalent in this population, 
and HSCT has a negative impact on nutritional status at discharge.
Keywords: Nutritional therapy; nutritional status; hematopoietic stem cell transplantation; 
pediatrics
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) is a complex therapeutic 
procedure whose objective is to induce immunosuppression and facilitate cell 
grafting and/or remove residual neoplasia through high-dose chemotherapy, 
with or without radiotherapy¹. HSCT is often preceded by a conditioning 
regimen, which may have adverse effects such as gastrointestinal toxicity, 
and ultimately affect nutritional status. Pediatric cancer patients who undergo 
HSCT are at even greater nutritional risk due to the combined effects of 
this procedure, the underlying illness and previous treatments². Malnutrition 
before and during the transplant is a known predictor of negative outcomes³. 
Thus, nutritional monitoring and the implementation of nutritional therapy 
(NT) are especially important strategies to counteract the catabolic effects 
of the disease and the transplant process in pediatric patients, who are 
in the growth and development phase. Enteral NT seems to offer several 
benefits, such as decreased adverse effects, costs and length of hospital 
stay4,5, especially with early implementation6. Therefore, the aim of this 
study is to describe the use of NT in children and adolescents submitted 
to autologous HSCT, and verify changes in nutritional status at hospital 
discharge after HSCT. 
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METHODS
A retrospective observational study was conducted on 
pediatric oncology patients hospitalized for autologous 
HSTC at the Pediatric Oncology Unit of the Hospital de 
Clínicas de Porto Alegre (HCPA), RS, Brazil. Inclusion 
criteria were patients aged 0 to 19 years who were 
hospitalized at the HCPA between 2010 and 2017. 
Patients who had no nutritional monitoring or therapy 
records were excluded from the study. Data were 
collected from electronic hospital records between 
June and September 2018. Patient characteristics were 
examined by collecting data on sex, age, race and type 
of hospitalization (public or private insurance), using 
a form created specifically for this study. The disease 
and oncological treatment were assessed based on 
the following variables: diagnosis, chemotherapy, 
radiotherapy and previous oncological surgery. The 
type of conditioning prior to transplantation was also 
considered. Nutritional status was evaluated at hospital 
admission and discharge, according to an institutional 
protocol that includes measurement of weight and 
height for the calculation of length/height for age, 
weight for age, weight for length/height and body 
mass index for age. Classifications were performed 
according to the World Health Organization7-9 criteria, 
using the WHO Anthro and Anthro Plus programs. 
For analysis, patients were classified into the following 
categories: underweight/at risk for underweight, 
normal, overweight/at risk for overweight and obesity. 
The number of days on exclusive oral intake (OI), 
enteral tube feeding (ETF), ETF + parenteral nutrition 
(ETF + PN) and parenteral nutrition (PN) during 
hospitalization were also evaluated. For patients who 
received ETF + PN, the time on NT was calculated 
by considering the overlapping days and those when 
only one of methods was used. Patients who received 
ETF or PN may or may not have had concomitant 
OI. Oral supplementation was not considered in this 
study. The length of hospital stay was calculated as 
the number of days between admission and discharge. 
The researchers signed a Data Use Agreement prior 
to conducting the study. This project was approved 
by the Research Ethics Committee of the Hospital de 
Clínicas de Porto Alegre, under No. 2,510,615 and 
CAAE 82639917.3.0000.5327.
Statistical analysis
Continuous variables are presented as median 
and interquartile range and categorical variables 
as frequencies and percentages. The relationship 
between quantitative and polytomous variables 
was assessed using the Kruskal Wallis test. 
The distribution of nutritional status at admission and 
discharge was compared using the McNemar test. 
For all tests, values of p < 0.05 were assumed to 
be significant. The analyses were conducted using 
STATA (version 14.0, StataCorp LP, USA).
RESULTS
Eighty-six patients were initially eligible for the 
study, but 18 were excluded due to missing data in their 
medical records, leaving a final sample of 68 patients. 
Most patients were boys (54.4%), identified as white 
(97.1%) and diagnosed with solid tumors (89.7%). 
Most participants (86.8%) were also admitted through 
the public health system (Table 1). The sample was 
equally divided between patients younger than 5 years 
and those aged 5 years or older (Table 1). Nutritional 
therapy was required in over half (52.9%) of cases, 
with 22.2% of these patients receiving ETF, 33.3% 
receiving ETF + PN and 44.5% receiving PN only. 
The type of NT used for the longest duration was 
ETF + PN. Patients classified as underweight or 
at risk for underweight received NT for longer than 
other participant groups (Table 2). The duration of 
hospitalization was longest for patients who received 
ETF + PN and PN. Though length of hospital stay 
did not significantly differ between nutritional status 
groups, patients classified as underweight or at risk 
for underweight had the highest median number of 
days in hospital (Table 3). Comparisons of nutritional 
status revealed a significant reduction in the percentage 
of at-risk/overweight patients (p = 0.008) and an 
increase in the percentage of at-risk/underweight 
patients (p = 0.001) from admission to discharge 
(Figure 1). No differences were noted in the frequency 
of normal weight (p = 0.647) or obesity (p => 0.999) 
(Figure 1). Two patients had missing anthropometric 
data, prohibiting the assessment of nutritional status 
at hospital discharge.






<5 years 34 (50.0)
≥ 5 years 34 (50.0)
Continues...
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Public health system 59 (86.8)
Private insurance 9 (13.2)
Diagnosis
Malignant solid tumor 61 (89.7)















Abbreviations:  MEC (Melphalan, Etoposide,Carboplatin); BUMEL (Busulfan, Melphalan). *Other: 5 (Carmustine, Etoposide, Cytarabine, 
Melphalan), 1 (Melphalan), 1 (Carboplatin, Thiotepa, Etoposide), 1 (Etoposide, Cyclophosphamide, Carboplatin).
Table 2: Duration of nutritional support by type and nutritional status (n=36).
n (%) Median (IQR) p value*
Days of NT by route 
ETF 8 (22.2) 13.5 (9.5; 22) 0.002
PN 16 (44.5) 11 (8; 16.5)
ETF + PN  12 (33.3) 27.5 (17.5; 35.5)
Days of NT by nutritional status 
Underweight/At risk 8 (22.2) 33.5 (23; 36) 0.002
Normal 22 (61.1) 14.5 (8; 23)
Overweight/At risk 6 (16.7) 11 (8; 12)
Obesity 0 -
Abbreviations: NT (nutrition therapy); PN (parenteral nutrition); ETF(enteral tube feeding), IQR (interquartile range). *Kruskal-Wallis test.
Table 3: Days of hospitalization by route of nutrition and nutritional status (n=68).
n (%) Median (IQR) p value*
Days of hospitalization  
OI 32 (47.1) 34.5 (30; 41.5) 0.009
ETF 8 (11.8) 28 (25.5; 39)
PN 16 (23.5) 41.5 (28.5; 46.5)
ETF + PN 12 (17.6) 50 (38.5; 55.5)
Days of hospitalization 
At risk/Underweight 11 (16.6) 43 (38; 56) 0.125
Normal 39 (59.1) 35 (28; 44)
At risk/Overweight 15 (22.7) 34 (30; 62)
Obesity 3 (4.5) 30 (30; 37)
Abbreviations: OI (oral intake); PN (parenteral nutrition); ETF (enteral tube feeding); IQR (interquartile range). *Kruskal-Wallis test.
Table 1: Continuation
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Figure 1: Nutritional status of patients receiving autologous hematopoietic stem cell transplant at hospital admission and 
discharge (n=66).
DISCUSSION
In the present study, significant changes in the 
distribution of nutritional status were observed from 
admission to discharge in patients who underwent 
HSCT. Additionally, over half the patients required 
NT via ETF and/or PN (52.9%). In a study conducted 
by Garófolo (2012), the main indications for ETF in 
patients who underwent autologous transplantation 
were: inadequate oral intake of food and supplements; 
insufficient intake of food and supplements with 
malnutrition or weight loss; and severe malnutrition10. 
The same study also reported that 36% of patients 
who underwent autologous HSCT had some degree 
of malnutrition at admission10. In the present study, 
the percentage of patients who were underweight 
or at risk for underweight at admission was 16.7%, 
and increased significantly to 33.3% at discharge. 
Though there has been an increase in the prevalence 
of overweight among healthy children in the general 
population11, those who are hospitalized for transplant 
are usually in the normal weight range10,12,13. This was 
observed in our study, where most patients were of 
normal weight in the pre-transplant period (59.1%), 
although this assessment did not consider body 
composition. The prevalence of obesity in the 
pre-transplant period was 4.5%, while that of overweight 
or risk for overweight was 22.7%. According to a study 
by White et al.12, children classified as overweight 
before autologous or allogeneic transplant have 
lower survival rates than those in the normal weight 
range; this finding underscores the importance of 
an adequate nutritional status in these patients. 
In a study on NT, Bicakli et al.13 demonstrated that 
pediatric patients who received enteral nutrition 
during hospitalization for HSTC gained weight, 
and the median duration of this diet was 21 days, 
supporting the tolerability of enteral nutrition. These 
authors also suggest enteral nutrition as a nutritional 
support strategy for pediatric patients undergoing 
HSCT13. In another study of pediatric patients receiving 
autologous HSCT, the authors found that PN could 
improve nutritional status and also contribute to the 
recovery of hematopoiesis after the transplant14. 
In our study, PN was the most commonly used method 
of nutritional support. While 44.5% of patients who 
received nutritional support were given PN only, 
the percentage of those who received PN either alone 
or in combination with ETF was 77.8%. According to 
the literature, PN is associated with a higher risk of 
infection and complications15,16. However, in clinical 
practice, it is sometimes the best available option for 
patients with a compromised gastrointestinal tract 
and other clinical complications. These observations 
underscore the importance of new studies comparing 
ETF and PN, as suggested by Bicakli et al.14 and 
also by Garófolo and Nakamura17; these authors 
note that there is little evidence to support nutritional 
recommendations and nutrition therapy for pediatric 
patients submitted to HSCT, but encourage the use 
of ETF based on their review of the literature and 
practical experience17. In the present study, patients 
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who received ETF had shorter hospital stays, even 
when compared to patients on a total oral diet. It should 
be noted that, in clinical practice, many patients on 
an oral diet with an indication for ETF or PN during 
the transplant period cannot receive these treatments 
due to accidental tube removal, lack of acceptance 
of the feeding tube, severe thrombocytopenia and/or 
neutropenia, oral mucositis, and lack of access/
catheter. As such, given the importance of nutritional 
management during the transplant period, future 
studies should evaluate the adequacy of OI and 
compare the prescribed and actual dietary intake of 
patients on an enteral diet, in order to determine the 
association between these variables and patients’ 
clinical outcomes. Few studies in the literature have 
explored these issues, and only a fraction of these 
have focused on pediatric patients18,19. A study by 
Andersen et al., for instance, demonstrated that 
gastrointestinal toxicity is related to poor tolerance of 
ETF if initiated once the patient has already reduced 
their food intake, leading to increased indications of 
PN5. In the present sample, all patients had some 
degree of gastrointestinal toxicity (data not shown). 
This may partially explain the high prevalence of PN 
and the longer hospital stays of patients in this sample. 
In this context, the early indication of ETF could also 
impact another relevant variable associated with NT 
and length of hospitalization: hospitalization costs. 
PN is known to be more costly than enteral formulas; 
therefore, if the early indication of ETF reduces the 
need for PN, the costs of nutritional support for these 
patients would also decrease.
CONCLUSION
Our findings revealed a worsening of nutritional 
status from admission to discharge in patients submitted 
to autologous HSCT, as well as a prevalent need for 
NT in this sample. PN was the most frequently used 
form of nutritional support, and patients who used 
ETF diet had shorter hospitalizations. Further studies 
are needed to identify the most appropriate form of 
NT and the best time to initiate nutritional support 
according to the clinical situation. This study had some 
limitations, such as its retrospective observational 
design and the number of patients excluded from 
the analysis due to missing data.
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